Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP03732397A	2010-01-21	Teva Pharmaceutical Industries Ltd.	Revoked
EP03732397A	2010-01-21	Sanovel Ilac Sanayii ve Ticaret A.S.	Revoked
EP03732397A	2010-01-21	KRKA, d.d., Novo mesto	Revoked
EP03732397A	2010-01-20	Lupin Limited	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101599	NOVARTIS	Pharmaceutical composition containing anti-hypertensive agents	May, 2023 (4 months ago)
US8475839	NOVARTIS	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	May, 2023 (4 months ago)
US8475839 (Pediatric)	NOVARTIS	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	Nov, 2023 (a month from now)

Exforge Hct is owned by Novartis.

Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.

Exforge Hct has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exforge Hct are:

Exforge Hct was authorised for market use on 30 April, 2009.

Exforge Hct is available in tablet;oral dosage forms.

The generics of Exforge Hct are possible to be released after 16 November, 2023.

Market Authorisation Date: 30 April, 2009

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 mg	14 Sep, 2009	1	25 Sep, 2012	18 Jul, 2017	Eligible
10 mg/12.5 mg/ 160 mg	22 Oct, 2009	1	25 Sep, 2012	18 Jul, 2017	Eligible

EXFORGE HCT family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic